NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Expected to Announce Earnings of -$0.27 Per Share

Wall Street brokerages expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) to announce earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for NeuBase Therapeutics’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.27). NeuBase Therapeutics posted earnings per share of ($0.20) during the same quarter last year, which would suggest a negative year-over-year growth rate of 35%. The firm is expected to issue its next earnings report on Wednesday, December 22nd.

On average, analysts expect that NeuBase Therapeutics will report full year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.88). For the next financial year, analysts anticipate that the firm will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.34) to ($0.87). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow NeuBase Therapeutics.

NBSE has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of NeuBase Therapeutics in a report on Monday, September 13th. Zacks Investment Research downgraded NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 16th.

Several institutional investors have recently made changes to their positions in the business. Greenlight Capital Inc. raised its holdings in shares of NeuBase Therapeutics by 34.5% during the second quarter. Greenlight Capital Inc. now owns 2,727,027 shares of the company’s stock valued at $13,062,000 after acquiring an additional 700,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of NeuBase Therapeutics by 35.4% during the second quarter. Vanguard Group Inc. now owns 1,297,848 shares of the company’s stock valued at $6,217,000 after acquiring an additional 339,017 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of NeuBase Therapeutics during the second quarter valued at approximately $5,988,000. Polar Asset Management Partners Inc. acquired a new position in shares of NeuBase Therapeutics during the first quarter valued at approximately $4,690,000. Finally, Renaissance Technologies LLC raised its holdings in shares of NeuBase Therapeutics by 116.9% during the second quarter. Renaissance Technologies LLC now owns 424,851 shares of the company’s stock valued at $2,035,000 after acquiring an additional 228,973 shares during the last quarter. 31.85% of the stock is owned by institutional investors and hedge funds.

Shares of NBSE stock opened at $3.80 on Tuesday. The stock’s 50-day simple moving average is $3.74 and its 200-day simple moving average is $5.21. The firm has a market capitalization of $124.32 million, a PE ratio of -4.18 and a beta of -0.01. NeuBase Therapeutics has a fifty-two week low of $3.26 and a fifty-two week high of $12.89.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy.

Featured Article: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on NeuBase Therapeutics (NBSE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeuBase Therapeutics (NASDAQ:NBSE)

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.